Your Cart

Appendix 2A — IBXOA Options

Appendix 2A — IBXOA Options

Imagion Biosystems Limited announces Appendix 2A — IBXOA Options.

Read the announcement.


Related Articles

1H2023 Half-Year Results

1H2023 Highlights: Achieved enrolment target for Phase I study of MagSense® HER2 breast cancer detection; imaging results corroborated by independent panel of radiologists Announced plan

Read More

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.